Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery. Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement. The company is eligible to receive over $100 million including upfront, milestone payments and tiered […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!